Found: 29
Select item for more details and to access through your institution.
Cabozantinib: a novel agent with a dual mechanism of action for castration-resistant prostate carcinoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 219, doi. 10.1007/s00280-013-2343-2
- By:
- Publication type:
- Article
Changes of cytokines in patients with liver cirrhosis and advanced hepatocellular carcinoma treated by sorafenib.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 223, doi. 10.1007/s00280-013-2344-1
- By:
- Publication type:
- Article
Phase I dose-escalation study of oral vinflunine in combination with erlotinib in pre-treated and unselected EGFR patients with locally advanced or metastatic non-small-cell lung cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 231, doi. 10.1007/s00280-013-2342-3
- By:
- Publication type:
- Article
Antitumor effects of BI-D1870 on human oral squamous cell carcinoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 237, doi. 10.1007/s00280-013-2349-9
- By:
- Publication type:
- Article
A phase I trial of flavopiridol in relapsed multiple myeloma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 249, doi. 10.1007/s00280-013-2347-y
- By:
- Publication type:
- Article
Vascular-targeted agents for the treatment of angiosarcoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 259, doi. 10.1007/s00280-013-2345-0
- By:
- Publication type:
- Article
p75 neurotrophin receptor and fenretinide-induced signaling in neuroblastoma.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 271, doi. 10.1007/s00280-013-2355-y
- By:
- Publication type:
- Article
Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 281, doi. 10.1007/s00280-013-2350-3
- By:
- Publication type:
- Article
Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS).
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 287, doi. 10.1007/s00280-013-2352-1
- By:
- Publication type:
- Article
Fractionation of daily dose increases the predicted risk of severe sorafenib-induced hand-foot syndrome (HFS)
- Published in:
- 2014
- By:
- Publication type:
- Journal Article
Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 299, doi. 10.1007/s00280-013-2356-x
- By:
- Publication type:
- Article
A phase I trial of combination therapy using gemcitabine and S-1 concurrent with full-dose radiation for resectable pancreatic cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 309, doi. 10.1007/s00280-013-2357-9
- By:
- Publication type:
- Article
Mechanisms affecting neutrophil migration capacity in breast cancer patients before and after chemotherapy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 317, doi. 10.1007/s00280-013-2348-x
- By:
- Publication type:
- Article
TS mRNA levels can predict pemetrexed and raltitrexed sensitivity in colorectal cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 325, doi. 10.1007/s00280-013-2354-z
- By:
- Publication type:
- Article
Prognostic role of microRNA polymorphisms in patients with advanced esophageal squamous cell carcinoma receiving platinum-based chemotherapy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 335, doi. 10.1007/s00280-013-2364-x
- By:
- Publication type:
- Article
Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 343, doi. 10.1007/s00280-013-2362-z
- By:
- Publication type:
- Article
Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors.
- Published in:
- 2014
- By:
- Publication type:
- journal article
Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy- d-glucose.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 349, doi. 10.1007/s00280-013-2358-8
- By:
- Publication type:
- Article
Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-D-glucose.
- Published in:
- 2014
- By:
- Publication type:
- journal article
A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid tumors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 363, doi. 10.1007/s00280-013-2361-0
- By:
- Publication type:
- Article
First-in-human phase II trial of the botanical formulation PHY906 with capecitabine as second-line therapy in patients with advanced pancreatic cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 373, doi. 10.1007/s00280-013-2359-7
- By:
- Publication type:
- Article
Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 381, doi. 10.1007/s00280-013-2360-1
- By:
- Publication type:
- Article
Randomized controlled study of gemcitabine plus S-1 combination chemotherapy versus gemcitabine for unresectable pancreatic cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 389, doi. 10.1007/s00280-013-2368-6
- By:
- Publication type:
- Article
Induction of DNA damage and p21-dependent senescence by Riccardin D is a novel mechanism contributing to its growth suppression in prostate cancer cells in vitro and in vivo.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 397, doi. 10.1007/s00280-013-2365-9
- By:
- Publication type:
- Article
CA19-9 level as a prognostic and predictive factor of bevacizumab efficacy in metastatic colorectal cancer patients undergoing oxaliplatin-based chemotherapy.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 409, doi. 10.1007/s00280-013-2367-7
- By:
- Publication type:
- Article
Targeting cisplatin-resistant human tumor cells with metabolic inhibitors.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 417, doi. 10.1007/s00280-013-2366-8
- By:
- Publication type:
- Article
Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2014, v. 73, n. 2, p. 429, doi. 10.1007/s00280-013-2353-0
- By:
- Publication type:
- Article
Assessing physico-chemical compatibility of concomitantly diluted antiemetics including palonosetron-HCl and fosaprepitant dimeglumine.
- Published in:
- 2014
- By:
- Publication type:
- Letter
Reply to: assessing physico-chemical compatibility of concomitantly diluted antiemetics including palonosetron-HCl and fosaprepitant dimeglumine.
- Published in:
- 2014
- By:
- Publication type:
- Letter